Delivery Order SPE2DB22D9130-SPE2DB25FE0EC

Award Date 5/6/25
Potential Completion Date 5/28/25
Potential Value $8.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the provision of Stelara 90 mg/ml syringes, a specialized pharmaceutical product, with a ceiling value of $16,441.36 and a period of performance through March 7, 2025. The contract is a firm fixed-price delivery order and is not associated with any set-aside designation, allowing...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of the drug Stelara 90 mg/ml syringe. The award, valued at $7,108.82, has a period of performance through May 10, 2024. This delivery order is placed under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group worth up to $499,999,999, which allows the DLA to issue firm fixed-price orders for a wide...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $32,882.72, is for the delivery of Stelara 90 mg/ml syringes. This order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive range of...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $8,220.68, is for the delivery of Stelara 90 mg/mL syringes. It is a firm fixed-price contract with a completion date of May 23, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026....
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $64,999.80, is for the delivery of Stelara 90 mg/ml syringe. It is a firm fixed-price delivery order contract with a period of performance ending on May 27, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $49,324.08 firm fixed-price contract is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables the DLA to...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, with a ceiling value of $98,648.16, is for the delivery of Stelara 90 mg/ml syringes. The contract is a Firm Fixed Price Delivery Order with a period of performance through May 8, 2025. The contract does not have a set-aside designation. This award is part of a larger Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $8,220.68, is for the delivery of Stelara 90 mg/ml syringes. The award is a firm fixed-price delivery order under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA, valued at $499,999,999 and valid through November 2026. This IDC allows the DLA to issue delivery orders for a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,220.68 award is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a period of performance through April 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $49,324.08, is for the delivery of Stelara 90 mg/mL syringes to support the medical supply needs of military health facilities. This contract award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the...
  • SPE2DB22D9130
    Indefinite Delivery Contract
  • SPE2DB22D9130-SPE2DB25FE0EC
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Stelara 90 mg/ml syringes, a prescription medication, with a ceiling value of $8,220.68 and a period of performance through May 28, 2025.

The award is made under a larger Indefinite Delivery Contract (IDC) vehicle that DMS Pharmaceutical Group holds with the DLA, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories.

This contract does not have a set-aside designation. DMS Pharmaceutical Group's status as a woman-owned small business allows it to compete effectively for federal pharmaceutical contracts without specific set-aside requirements.

Generated 8/10/25, 1:07 AM